Source comparison
CJC-1295 MK-677 Stack Comparison — Protocol Variations and Outcomes
| Protocol Variant | CJC-1295 Dose | MK-677 Dose | Dosing Frequency | Sustained GH Duration | Typical Use Case | Professional Assessment ||—|—|—|—|—|—|| Standard Research Protocol | 1.5mg | 20mg daily | CJC: 2×/week | 18–22 hours post-CJC dose | General GH ele
This comparison does not assign a generated winner or score.
- | Protocol Variant | CJC-1295 Dose | MK-677 Dose | Dosing Frequency | Sustained GH Duration | Typical Use Case | Professional Assessment ||—|—|—|—|—|—|| Standard Research Protocol | 1.5mg | 20mg daily | CJC: 2×/week | 18–22 hours post-CJC dose | General GH elevation studies | Proven efficacy; most validated in published literature. Timing coordination essential for synergy. || Extended Elevation Protocol | 2mg | 25mg daily | CJC: 2×/week | 20–24 hours post-CJC dose | Body composition research, metabolic studies | Higher GH output but increased appetite and transient insulin resistance side effects at MK-677 25mg dose. || Conservative Titration Protocol | 1mg | 12.5mg daily | CJC: 1×/week | 14–18 hours post-CJC dose | Initial research phase, elderly populations | Lower side effect incidence; reduced synergistic magnitude. Suitable for dose-finding studies. || Pulsatile-Focus Protocol | 1mg | 12.5mg every other day | CJC: 2×/week | 12–16 hours post-CJC dose | Studies prioritizing natural
- The Standard Research Protocol dominates current published studies because it balances efficacy with tolerability. The 1.5mg CJC-1295 dose twice weekly maintains plasma peptide concentration above the threshold for consistent GHRH receptor activation without causing receptor desensitization, which becomes a concern at doses above 2.5mg weekly. The 20mg daily MK-677 dose produces measurable GH elevation in 85–90% of research subjects across body weight ranges of 60–95kg.
- Extended Elevation protocols using 2mg CJC-1295 and 25mg MK-677 push sustained GH duration toward the 24-hour ceiling but introduce tolerability challenges. MK-677 at 25mg significantly increases appetite (ghrelin receptor activation in the hypothalamus stimulates hunger signaling), which complicates body composition studies where caloric intake must be controlled. Additionally, 25mg doses produce transient insulin resistance lasting 4–6 hours post-administration. Plasma glucose rises 10–15mg/dL, and insulin sensitivity decreases approximately 20%. That effect is temporary and reverses within 8–10 hours, but it complicates glucose-focused metabolic research.